The Board of Directors finalized the decision to acquire these shares at 100 percent of their quotient value, which equates to roughly SEK 0.55 per share. This operation is conditional upon subscription and payment by Svenska Handelsbanken AB. Once the repurchase is complete, the company plans to convert these class C shares into common shares, increasing its total holding of treasury common shares to 10,290,974.

Currently, Sobi maintains 10,067,297 common shares in its treasury and holds no class C shares. The firm, which focuses on rare disease therapies, reported SEK 28 billion in revenue for 2025 and employs approximately 2,000 people globally. The repurchase window remains open through early November, ensuring the company fulfills its commitments to its internal All Employee Programme.